ORYX identifies and develops highly innovative translational immunotherapy projects in cancer indications with high unmet medical need. The Company invests in promising R&D projects from academia and develops these through clinical proof of concept trials before partnering for further clinical development and commercialization.
The careful, multilevel selection of R&D projects results in a higher probability of success in the clinical development process. All ORYX selected projects, including the oncolytic virus and two therapeutic vaccines, have qualified for further clinical development and all have successfully completed Phase I/IIa trials in 2015 confirming both safety and efficacy.
The ORYX management, headed by Dr. Bernard Huber, comprises a team of experts with a longstanding track record in translational medicine projects and drug development, which is supported by a first-class scientific and clinical advisory board.
ORYX was founded in 2007 and is financed by a group of highly motivated private investors.